- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
top
On July 24, 2020, the European Medicines Agency (EMA) announced a positive regulatory opinion from on the Dapivirine Vaginal Ring as an HIV prevention option for cisgender women age 18 and older. This document helps advocates to understand the steps that can and must be taken now that the EMA has provided its opinion. Read it here.